Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2019

Continued progress with our proprietary and wholly owned candidate drug MIV-818 for liver cancer October – DecemberSignificant events during the quarter · Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also modulates the anti-tumor immune response, presented at the AACR-NCI-EORTC conference in Boston. · The ninth and final liver cancer patient was included in the phase Ia study with MIV-818. Based on safety and tolerability as well as pharmaco-kinetics and positive biomarker data, it was decided to initiate the phase Ib part of the study.

Stora Enso’s Annual Report 2019 published

STORA ENSO OYJ ANNUAL FINANCIAL REPORT 13 February 2020 at 9.30 EET Stora Enso’s Annual Report 2019 has been published at storaenso.com/annualreport . The Annual Report 2019 consists of four sections: Strategy, Sustainability, Financials and Governance. Strategy explains how our transformation is progressing and how we create value as a renewable materials company, highlighting key events from all divisions. Sustainability covers Stora Enso’s social, environmental, and economic sustainability performance. Financials consists of the report of

NRC Group ASA: Key information relating to subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange published by NRC Group ASA (the "Company") on 12 February 2020, regarding a private placement of 18,918,919 new shares in the Company (the "Private Placement") and a subsequent offering of up to 1,891,892 new shares at the same

The Nomination Committee's proposal regarding the Board of Humana for the 2020 AGM

Ahead of the Annual General Meeting 2020 the Nomination Committee of Humana AB has decided to propose Karita Bekkemellem and Anders Nyberg as new directors of the Board.The Nomination Committee proposes that the Board be composed of seven directors (unchanged from the current year) elected at the Annual General Meeting, with no alternates, for the period until the next Annual General Meeting The Nomination Committee proposes re-election of Magdalena Gerger, Kirsi Komi, Monica Lingegård, Sören Mellstig and Fredrik Strömholm as directors and election of Karita Bekkemellem and Anders Nyberg

Notice of the Annual General Meeting of Terveystalo 2020

Stock Exchange Release 13 February 2020 at 9:01 EET Notice is given to the shareholders of Terveystalo Plc of the Annual General Meeting to be held on Thursday, 2 April 2020 at 3:00 p.m. at Finlandia Hall, Mannerheimintie 13e, Helsinki, Finland. The reception of attendees, who have registered for the meeting, will commence at 2:00 p.m. A. Matters on the agenda of the Annual General Meeting The following matters will be considered at the Annual General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to

Citycon Oyj: Managers’ Transactions

CITYCON OYJ   Managers’ Transactions   13 February 2020 at 9:00 hrsPerson subject to the notification requirement: Arnold de Haan, Member of the BoardIssuer: Citycon Oyj, LEI 549300P8N0P6KDGTJ206Notification type: initial notificationReference number: 549300P8N0P6KDGTJ206_20200212133832_4 1) TransactionDate: 10 February 2020Venue: NASDAQ HELSINKI LTD (XHEL)Nature of the transaction: disposalInstrumentshare (CTY1S)ISIN Code: FI4000369947Transaction detailsvolume: 35,974unit price: 9.60633 EURAggregated transactionstotal volume: 35,974volume weighted average

Flexion Mobile Plc - Q3 Report 31 December 2019

Flexion hits new quarterly revenue record during the busy Black Friday and Christmas period. The third financial quarter recorded total revenue of GBP 2.5m representing 41% growth (YoY). The Company signed two new titles and announced a partnership with Huawei’s App Gallery.October 2019 to December 2019 performance · Total revenue increased by 41% to GBP 2.5m (GBP 1.8m)* · Gross profit increased by 26% to GBP 0.3m (GBP 0.2m) · Adjusted EBITDA improved by 26% to GBP -0.5m (GBP -0.7m) · Operating loss reduced by 22% to GBP -0.6m (GBP -0.7m) · Earnings per share amounted to

Viking Line: Year-End Report for the period January - December 2019

Viking Line Abp       YEAR-END REPORT               13.2.2020, 9.00 AM Viking Line doubles its earnings January–December 2019 (compared to January–December 2018) · Sales amounted to EUR 496.4 M (497.8). · Other operating revenue was EUR 0.4 M (0.3). · Operating income totalled EUR 17.4 M (9.3). · Net financial items were EUR -3.8 M (-2.8). · Income before taxes amounted to EUR 13.6 M (6.5). · Income after taxes totalled EUR 10.8 M (5.5). Fourth quarter 2019 (compared to fourth quarter 2018) · Sales amounted to EUR 115.6 M (119.8). · Operating income

OssDsign AB (publ) publishes year-end report 2019

OssDsign CEO Anders Lundqvist: “OssDsign AB finished an exciting and eventful year on a very strong note. Our strategy for, and investments in the US market, as presented in the IPO process generated the expected good results.”The fourth quarter in figures · Net sales amounted to TSEK 5 069 (4 220).  · Loss after taxes amounted to TSEK 28 641 (15 755). · Loss per share was SEK 1,6 (2,8). · Cash flow from current operations was TSEK -24 023 (-26 887).  The full year in figures · Net sales amounted to TSEK 16 873 (13 264). · Loss after taxes amounted to TSEK 84 245 (

Humana reports fourth quarter and full year 2019

A weak finish to an eventful yearQ4, October–December 2019 · Operating revenue was SEK 1,912m (1,700), an increase of 12%, of which organic growth was 0.7%. · Operating profit was SEK 71m (82), a decrease of 13%. The profit was affected by integration costs of SEK -6m (-) for Coronaria Hoiva. The effects of IFRS 16, the new accounting standard that came into effect on 1 January 2019, on operating profit amounted to SEK 16m (-). · Net profit after tax for the period amounted to SEK 18m (51). · Earnings per share for the period before and after dilution amounted to SEK 0.35 (0.

Consistent strategy provides continued profitable growth

Summary of the period, January–December 2019 · Net sales SEK 1 156 million (1 017) · EBITA SEK 247 million (212), with an EBITA margin of 21% (21) · Operating profit SEK 144 million (128), with an operating margin of 12% (13) · Profit after net financial items was SEK 130 million (117) · Earnings per share before dilution SEK 3.16 (3.23) · Cash flow from operating activities SEK 278 million (197) · The Board of Directors propose a dividend increase to SEK  1.35 per share (1.20) Summary of the period, October–December 2019 · Net sales 298 million (290) · EBITA

TOMRA: Invitation to Q4 2019 Presentation

TOMRA's fourth quarter 2019 results will be released Thursday 20[th] of February 2020. President & CEO Stefan Ranstrand and CFO Espen Gundersen will present the results at 08:00 CET (UTC+1h). The presentation will be held in English and take place at Thon Hotel Vika Atrium, Oslo Norway (Meeting room: Nyland). The presentation will also be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast

Sobi publishes report for the fourth quarter and full-year 2019

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56 per cent with revenue of SEK 14,248 M. Adjusted EBITA was SEK 6,145 M, resulting in an adjusted EBITA margin of 43 per cent for the full year. October—December · Total revenue of SEK 4,890 M (2,571), 90 per cent revenue growth in the quarter compared with Q4 2018 (82 per cent at constant exchange rates (CER)) · Adjusted EBITA[1,2] was SEK 2,380 M (916), an increase of 160 per cent · Earnings per share (

Year-end report January-December 2019

Increased profitability enables further growth investmentsThe fourth quarter · Net sales amounted to MSEK 81.8 (68.9), rendering a net sales growth of 19 % (20 %). Organic net sales growth was 14 % (19 %) · Recurring revenue amounted to MSEK 44.3 (37.1) · The quarter was impacted by one-off items affecting comparison amounting to MSEK 0.0 (6.9). The comparison figure is attributable to the listing of the company’s shares on Nasdaq Stockholm. · Adjusted EBITA amounted to MSEK 20 (16) which corresponds to an adjusted EBITA margin of 24 % (23 %) · Net income amounted to MSEK

Terveystalo Group Financial Statements Bulletin 2019

Strong revenue growth and profitability Terveystalo Plc, Financial Statements Bulletin, 13 February 2020 at 9:00 EET This release is a summary of Terveystalo's Financial Statements Bulletin 2019. The full release is attached to this stock exchange release and is available on our website at: https://www.terveystalo.com/en/investors/Financial-information/. October–December 2019 in brief · Revenue increased by 36.6 percent year-on-year to EUR 270.3 million (197.9) · Adjusted[1)] earnings before interest, taxes and amortization (EBITA) before IFRS 16 impact (comparable)

Ziccum AB (publ) Year-end report January 1 – December 31, 2019

LUND, SWEDEN – 13 February 2020. Ziccum AB (publ), summary of the year-end report - fourth quarter 2019: Ziccum is well on its way to delivering what we promised when listing our share - to start three projects during the year to develop stable, dry vaccine formulations as well as biological drugs.CEO Statement Ziccum has a unique, patented technology - LaminarPaceTM - that enables us to manufacture biological drugs in dry form. In principle, dry form is always sought after in the development of new drugs and the benefits are many. It increases the stability of the product and thus its

Attendo's year-end report for 2019 – Good organic growth but weak profitability in Finland persists

Attendo continued to show good organic growth during the fourth quarter as well as for the full year 2019. Profitability in Attendo Scandinavia remained stable, while Attendo Finland remained under pressure. Work to restore confidence and profitability in Finland is ongoing, but the financial effects will come later in 2020.President and CEO Martin Tivéus comments on the report “We opened almost two thousand new beds in own operations during the year and laid the foundation for future organic growth. In parallel, the high rate of establishment in Finland in recent years has constrained

Munters Q4 and Year-end report 2019

”Platform for the future strengthened in 2019”Fourth Quarter 2019 · Market demand mixed with areas of good growth. Order intake and net sales increased by 6% respective 5% and were flat organically, on the back of a strong fourth quarter 2018 · Order intake mainly driven by larger order in Data Centers US, whereas the industrial segment saw weaker demand. Business area FoodTech grew in the US and Asia · Net sales increased in business area AirTech, where as business area FoodTech net sales declined despite good growth in Asia · Adjusted EBITA margin was slightly lower compared

NENT Group appoints My Perrone as SVP & General Counsel

Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, has appointed My Perrone as Senior Vice President and General Counsel with immediate effect. My, who will now be responsible for the company’s legal operations and lead NENT Group’s legal team, has been acting General Counsel since June 2019, prior to which she was Head of Legal Sweden.In her new role, My will be a member of NENT Group’s extended Group Executive Management team. NENT Group’s legal team is part of the Corporate Affairs function. Matthew Hooper, NENT Group EVP & Chief Corporate Affairs

Kojamo plc: Notice to the Annual General Meeting of Kojamo plc

Kojamo plc Stock Exchange Release 13 February 2020 at 9:00 a.m. EETNotice to the Annual General Meeting of Kojamo plc Notice is given to the shareholders of Kojamo plc to the Annual General Meeting to be held on Thursday, 12 March 2020 at 10:00 a.m. (Finnish time) in the Pörssisali room of Pörssitalo (the Helsinki stock exchange building), at the address Fabianinkatu 14, 00100 Helsinki. The reception of persons who have registered for the Annual General Meeting and the distribution of voting tickets will commence at the venue at 09:00 a.m. A. MATTERS ON THE AGENDA FOR THE ANNUAL

Year-end Report Q4, January-December 2019

October – December 2019 · Net sales decreased to SEK 568 million (603) · Operating profit before depreciation increased to SEK 36 million (5) including IFRS 16 impact of SEK 15 million · Operating profit increased to SEK 14 million (-85) · Earnings after tax amounted to SEK -1 million (-123) · Earnings per share amounted to SEK 0.00 (-0.58) · Cash flow after investing activities amounted to SEK 55 million (-6) including IFRS 16 impact of SEK 13 million January – December 2019 · Net sales decreased to SEK 2,166 million (2,220) · Operating profit before

Atria Plc, Financial Statement Release, 1 January–31 December 2019: Atria's financial performance continued strong during the fourth quarter

Atria Plc, Financial Statement Release, 13 February 2020, 8:00 amAtria Plc, Financial Statement Release, 1 January – 31 December 2019Atria's financial performance continued strong during the fourth quarterOctober–December 2019- Consolidated net sales totalled EUR 380.0 million (EUR 376.9 million).- Consolidated EBIT was EUR 12.1 million (EUR 6.7 million), which is 3.2 per cent (1.8%) of net sales.- Atria Finland’s profitability improved significantly. Exports of pork to China continued to increase.- The positive development of Atria Sweden’s EBIT continued in the fourth

Raute Corporation - Financial statements release January 1 - December 31, 2019

RAUTE CORPORATION FINANCIAL STATEMENTS RELEASE FEBRUARY 13, 2020 AT 9:00 A.M. RAUTE CORPORATION – FINANCIAL STATEMENTS JANUARY 1 – DECEMBER 31, 2019 This is a summary of Raute’s Financial statements release January 1 – December 31, 2019. The full report is a PDF file attachment to this stock exchange release and is also available on the company's website at www.raute.com. - The Group’s net sales EUR 151.3 million (MEUR 181.0) fell by 16% on the comparison year. Order intake, at EUR 148 million (MEUR 167), was at a good level, although it fell 11%. The order book at the end of the

Mineral Resources and Mineral Reserves 2019

There was continued successful exploration in Tara in 2019, while the Mineral Reserve in Kevitsa has also increased. Garpenberg and Aitik have Mineral Resources and Mineral Reserves that will secure production for many years to come.“Mineral Reserves are increasing at our open pit mines and this is an important development. The focus within underground mines is now on Tara and the Boliden Area, where we are developing the deposits we have identified,” says Stefan Romedahl, President Business Area Mines. Exploration costs in 2019 were SEK 570 million (520). AitikThere is no large-

There are no items matching the current filter
There are no more items matching the current filter
Back to top